Research Article | Open Access
Tania Rivera-Baltanas, Raquel Romay-Tallon, Iria G. Dopeso-Reyes, Héctor J. Caruncho, "Serotonin Transporter Clustering in Blood Lymphocytes of Reeler Mice", Cardiovascular Psychiatry and Neurology, vol. 2010, Article ID 396282, 7 pages, 2010. https://doi.org/10.1155/2010/396282
Serotonin Transporter Clustering in Blood Lymphocytes of Reeler Mice
Serotonin transporter clustering is an important feature for regulation of this transporter activity. We used immunocytochemistry to analyze alterations in serotonin transporter clustering in blood lymphocytes of reeler mice. Serotonin transporter immunolabelling is observed mostly as a patchy staining in lymphocytes membranes. Comparison of the number and size of serotonin transporter clusters in wild-type mice, heterozygous reeler mice, and homozygous reeler mice showed an increase in the number and size of clusters in heterozygous reeler mice, but only an increase in clusters size in homozygous reeler mice. Reelin is down-regulated in the brain of schizophrenia, autism, and mood disorders, and is also expressed in blood plasma. There is the possibility therefore that alterations in serotonin transporter clustering in blood lymphocytes associated with a decrease in reelin expression may be operative in some cardiovascular or immune system alterations showing comorbidity with these mental disorders.
Protein clustering into specific membrane domains is known to be of importance for membrane proteins functional regulation: the clustering of neurotransmitter receptors into postsynaptic active sites, the formation of the immunological synapse, the partitioning of membrane proteins into lipid raft domains, and the clustering of membrane proteins to be internalized are good examples of that.
The serotonin transporter (SERT) belongs to the SLC6 family of sodium- and chloride-dependent integral membrane proteins, and is the primary responsible for the recapture of released serotonin from the extracellular space [1, 2]. The clustering of SERT into specific membrane domains such as lipid rafts , SERT oligomerization [4, 5], and SERT subcellular distribution  appears to be critical for serotonin reuptake activity. SERT is one of the main targets of antidepressant medication, and alterations in SERT expression and activity have been found both in mood and psychotic disorders. In fact, a decrease in SERT binding in blood platelets is one of the best-characterized biomarkers of depression , and a similar decrease has also been found in peripheral lymphocytes in depression [8–10].
Reelin is a large extracellular matrix protein abundant in brain tissue whose levels are down-regulated in several psychiatric disorders [11–15]. Reelin is also expressed in blood plasma , and alterations in reelin plasma levels are also found in different psychiatric disorders such as schizophrenia, mood disorders, and autism [14, 17], although an accurate measurement of reelin plasma levels is not easily accomplished due to its sensitivity to proteolysis and freeze-thawing cycles .
The primary actions of reelin in the nervous systems are regulating neural migration and synaptogenesis in cortical areas during brain development (i.e., cerebral cortex, hippocampus, olfactory bulb, and cerebellum), and later in stabilizing synaptic contacts onto dendritic spines in the adult brain thereby regulating synaptic plasticity (see [19–21]). These actions are mediated at the molecular level by the interaction of reelin with ApoER2-VLDLR receptors, and bring about the phosphorylation of the adaptor protein DAB1 and activation of nonreceptor tyrosine kinases (see as reviews [20, 21]). In addition, reelin also binds integrin receptors resulting in the upregulation of specific mRNAs translation in dendritic spines , and an increase in number and clustering of intramembrane particles (i.e., transmembrane proteins) in postsynaptic membrane domains .
While reelin actions in the nervous system are well studied, there is not so much knowledge about the possible actions of reelin in blood plasma, although it is known that reelin plasma is mostly secreted by hepatocytes , and is processed by plasminogen activator and plasmin .
Homozygous reeler mice () show no detectable levels of reelin in plasma, while the happloinssuficient heterozygous reeler mice () express reelin plasma levels about one half of those in wild-type () littermates , becoming a good model to analyze the effects that reelin down-regulation or null expression may induce in blood cells.
In the present report, we hypothesize that reelin may have an influence in clustering of membrane proteins in lymphocytes, and analyze the alterations observed in the clustering of SERT in peripheral lymphocytes in and mice, in comparison to mice.
2. Materials and Methods
2.1. Animals and Collection of Lymphocytes
We have used a total of 48 adult male mice in this experiment: 16 wild-type mice (), 16 heterozygous reeler mice (), and 16 reeler mice (). The animals were obtained from heterozygous breeding pairs (Jackson Laboratory, Bar Harbor, ME). Genotyping was performed by PCR using the following primers: TAATCTGTCCTCACTCGTCC , ACAGTTGACATACCTTAATC , TGCATTAATGTCGACTGTTGT . The PCR products were subsequently analyzed in a gel of 2% agarose.
Animal handling and maintenance, as well as all experimental procedures, were conducted in accordance with the European Communities Council Directive of 24 November 1986 (86/609/EEC) and Spanish Royal Decree of 14 March 1988 (223/1988/BOE). The performed experiments also received the approval of the ethics committee of the University of Santiago de Compostela.
Mice were anesthetized by IP injection of 15% chloral hydrate. Blood was collected from the orbits after enucleation of the eyes, followed by euthanasia by cervical dislocation. This procedure allowed to obtain up to 1 mL of blood per animal that was collected with ACD as anticoagulant (85 mM trisodium citrate, 65 mM citric acid, 111 mM anhydrous glucose), at a ratio 1 : 6 (v/v). Blood samples diluted 1 : 1 in 0.9% NaCl were centrifuged in a Percoll gradient for 20 minutes at 800 g, to collect the lymphocytes in the upper layer of the Percoll gradient. The lymphocytes were resuspended in saline solution and centrifuged at 1000 g for 10 minutes. After repeating the procedure, cells were resuspended in 1 mL of saline solution, and fixed for 1 minute in a solution of 1% paraformaldehyde in phosphate buffer at RT. Afterwards, cells were maintained for up to one week at in 1 mL of saline solution.
Immunolabelling of SERT was performed by consecutive centrifugation and resuspension of the lymphocyte samples in every step. The procedure involved first the incubation of the samples for 10 minutes at , in a solution of 100 mL of mice IgG (Sigma), diluted in PBS with 1%BSA, to block membrane immunoglobulins. It followed the incubation for 12 hours at with a solution of the primary antibody (Rabbit anti SERT, Chemicon) diluted 1 : 100 in PBS with 1%BSA. After washing, the samples were incubated in the dark, for 1 hour at RT with the secondary antibody (Goat antirabbit conjugated with Alexa Fluor 488, Molecular Probes) diluted 1 : 200 in PBS with 1%BSA. After repeated washing, samples were extended on slides and coverslipped and mounted with Moviol medium (Calbiochem). The samples were maintained at , untill analysis by confocal microscopy.
Samples were studied and lymphocyte photographs obtained in a laser confocal microscope Leica TCS-SP2. Photomicrographs were collected of 100 lymphocytes per sample. Control experiments by omitting the primary antibody resulted in a lack of immunoreactivity.
2.3. Data Analysis and Statistics
SERT labelling as obtained in confocal micrographs was analyzed by using ImageJ 1.42 imaging software (National Institutes of Health). The number of lymphocytes analyzed was 100 per animal (16 animals per group). The imaging system allowed carrying out an automatic counting of the number of SERT clusters per lymphocyte, of the size of those clusters, and also the percentage of the lymphocytes surface occupied by those clusters. In addition, the system allowed performing a surface plot indicating the intensity of fluorescence labeling per cluster. Statistical analysis was done using One way ANOVA followed by Kruskal-Wallis posthoc test. The statistical significance was established at .
The direct observation of SERT immunolabelling in lymphocytes of reeler mice shows that SERT clusters are more clearly seen in mice lymphocytes, while in both and mice lymphocytes, SERT staining is more fuzzy and of a lower intensity, as can be seen in surface plot images (Figures 1(a)–1(f)).
Statistical analysis of data indicates that the number of SERT immunopositive clusters per lymphocyte is increased about 50% in mice in comparison with wild-type mice (Figure 2(a) and Table 1), while in mice the number of SERT immunopositive clusters is similar to that of wild-type mice, and therefore, lower than in mice (Figure 2(a) and Table 1).
|Statistical significance set at . |
a, b, d. Different than in and mice.
c, e. Different than in and mice.
The average size of SERT immunopositive clusters is increased about 27% in mice in comparison to wild-type mice, while in reeler mice (), the average size of SERT clusters more than doubles that of wild-type mice (and increase of 109%), and is about 64% larger than in heterozygous reeler mice ( (Figure 2(b) and Table 1).
The percentage of the lymphocytes surface occupied by SERT immunopositive clusters is also increased in both mice (a 50% increase) and mice (an increase of 119%) with respect to wild-type mice (Figure 2(c) and Table 1). In addition, there is an increase of about 47% in the same value in mice in comparison with mice (Figure 2(c) and Table 1).
The graphic representation of the distribution of SERT clusters size in lymphocytes evidences that about 60% of the clusters are comprised in the interval of 0.05–0.1 m2 in wild-type mice, while this percentage is only of about 40% in lymphocytes of mice, and 30% in mice (Figure 3).
As far as we know this is the first attempt to study alterations of SERT clustering in blood lymphocytes of reeler mice. The results show that a down-regulation of about one-half of plasma reelin levels such as that observed in mice brings about an increase in the number of SERT clusters and also an increase in clusters size, whereas in mice (showing null expression of reelin) the number of SERT clusters is similar to that observed in mice, but of a much larger size than not only those in mice, but also of those in mice.
In case of a possible replication of these studies, it is essential to consider the fixative employed, the time of fixation, and the temperature at which the experiments were performed, because all of these parameters can affect the degree of membrane proteins clustering: for example, experiments of labelling of lipid raft markers showed that an increase in the amount of fixative tends to reduce the labelling of membrane markers, while a decrease in the amount of fixative and/or a decrease in the temperature of fixation tends to increase the size of lipid raft clusters as ascertained by immunolabelling .
Many reports have focussed on brain and behavioural alterations in both reeler and heterozygous reeler mice (see [25–28]); however, there are no so many studies on blood cells alterations in reeler mice. Interestingly, a report by Green-Johnson et al.  shows a suppression of T cell and macrophage function in reeler mice. These authors showed a decrease in proliferation of CD3-positive splenic T cells in mice (but not in mice) after activation of the immune system by injection with anti-CD3 antibodies for three days, and also a decrease in production of IL-2, IL-4 and interferon in mice, while there was only a significant decrease in the production of IL-4 (but not in the other parameters) by mice . At the time of this publication (1995), there was no evidence of reelin expression in blood plasma, and so the authors were discussing the possibility that the alterations found in T-cell lymphocytes could be related to alterations in the nervous system (mostly in the cerebellum) of mice. However, with the discovery of reelin expression in blood plasma, it seems more possible that there could be a direct connection between the decrease of reelin levels in blood plasma and the alterations observed in T cells in mice. Our data shows an increase in SERT clusters size in both and mice, although this increase is much higher in mice where SERT clusters average size is more than double of that in mice and more than 60% larger than in mice. In addition, surface plots of SERT immunofluorescence appear to indicate a decrease in the intensity of labeling per cluster that is more pronounced in lymphocytes, and the number of SERT-positive clusters is increased in mice but not in mice. This could be interpreted as an alteration in SERT clustering, reflecting an accumulation of SERT in clusters of small size in mice, while a decrease in reelin expression brings about the spread out of SERT in clusters of larger size. The clustering of SERT in lipid raft domains is important for SERT functional roles , and it is possible that a decrease in reelin levels could bring about an alteration of this clustering. In mice, the spread out of SERT in lymphocytes membranes is much lower than that in mice, and in addition there is a 50% increase in the number of SERT clusters in mice that could represent a compensatory mechanism that is not evident in mice. Both of these facts could perhaps explain in part the much lower alterations in T cells in mice than in mice observed by Green-Johnson et al. .
Reelin has been shown to induce the expression and clustering of some transmembrane proteins in synaptosomes , induces the clustering of its own receptors , and regulates NMDA receptor surface trafficking , therefore, it is not surprising that there is a spread out of SERT labelling in the membrane of lymphocytes in and mice. In fact, it is possible that reelin may be involved in regulating the clustering of multiple membrane proteins, including some neurotransmitter receptors and transporters. Although brain serotonin levels appear to be unaltered in mice, both and mice show an increase in brain serotonin levels upon early maternal separation of the pups . In addition, at least in mice there are important alterations in serotonergic innervations in the neocortex . Therefore, we are currently studying possible alterations in SERT clustering in the brain of these mice. Reelin is down-regulated in schizophrenia, autism, and mood disorders, showing a general decrease in different brain areas in schizophrenia, autism, and bipolar disorder, while there could be a more specific decrease in major depressive disorder [11–14]. Reelin levels and its processing are also altered in blood plasma of schizophrenia, autism, and mood disorders [14, 17]. Interestingly, brain and plasma reelin levels are highly downregulated in autism [14, 34–38], a disorder that is also characterized by blood hyperserotonemia [39, 40]. Taking into account the alterations in SERT clustering in lymphocytes of reelin-deficient mice shown in this report, one should consider the possibility of a similar alteration in lymphocytes of autistic patients that have both low plasma reelin levels and high plasma serotonin levels. In addition, it would be of interest to study a possible relation between the low levels of plasma reelin and the blood hyperserotonemia observed in these patients, as well as a possible increase in serotonin levels in blood plasma in reelin-deficient mice.
The results of the present report also invite to consider the actions of plasma reelin actions in SERT clustering in lymphocytes as a possible factor of importance in understanding the comorbidities between some immune and/or vascular systems alterations and these mental disorders.
The paper is supported by Grants SAF2007-62766 from Spanish Ministry of Science and Technology and FEDER, and PGIDIT06PXIB200166PR from Xunta de Galicia, to Héctor J. Caruncho.
- S. Horschitz, R. Hummerich, and P. Schloss, “Structure, function and regulation of the 5-hydroxytryptamine (serotonin) transporter,” Biochemical Society Transactions, vol. 29, no. 6, pp. 728–732, 2001.
- G. Rudnick, “Serotonin transporters—structure and function,” Journal of Membrane Biology, vol. 213, no. 2, pp. 101–110, 2006.
- F. Magnani, C. G. Tate, S. Wynne, C. Williams, and J. Haase, “Partitioning of the serotonin transporter into lipid microdomains modulates transport of serotonin,” The Journal of Biological Chemistry, vol. 279, no. 37, pp. 38770–38778, 2004.
- J. A. Schmid, H. Just, and H. H. Sitte, “Impact of oligomerization on the function of the human serotonin transporter,” Biochemical Society Transactions, vol. 29, no. 6, pp. 732–736, 2001.
- H. Just, H. H. Sitte, J. A. Schmid, M. Freissmuth, and O. Kudlacek, “Identification of an additional interaction domain in transmembrane domains 11 and 12 that supports oligomer formation in the human serotonin transporter,” The Journal of Biological Chemistry, vol. 279, no. 8, pp. 6650–6657, 2004.
- H. K. Müller, O. Wiborg, and J. Haase, “Subcellular redistribution of the serotonin transporter by secretory carrier membrane protein 2,” The Journal of Biological Chemistry, vol. 281, no. 39, pp. 28901–28909, 2006.
- R. Mössner, O. Mikova, E. Koutsilieri et al., “Consensus paper of the WFSBP task force on biological markers: biological markers in depression,” World Journal of Biological Psychiatry, vol. 8, no. 3, pp. 141–174, 2007.
- M. Urbina, S. Pineda, L. Piñango, I. Carreira, and L. Lima, “Paroxetine binding to human peripheral lymphocyte membranes of patients with major depression before and after treatment with fluoxetine,” International Journal of Immunopharmacology, vol. 21, no. 10, pp. 631–646, 1999.
- L. Lima and M. Urbina, “Serotonin transporter modulation in blood lymphocytes from patients with major depression,” Cellular and Molecular Neurobiology, vol. 22, no. 5-6, pp. 797–804, 2002.
- S. Peña, E. Baccichet, M. Urbina, I. Carreira, and L. Lima, “Effect of mirtazapine treatment on serotonin transporter in blood peripheral lymphocytes of major depression patients,” International Immunopharmacology, vol. 5, no. 6, pp. 1069–1076, 2005.
- F. Impagnatiello, A. Guidotti, C. Pesold et al., “A decrease of reelin expression as a putative vulnerability factor in schizophrenia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 26, pp. 15718–15723, 1998.
- A. Guidotti, J. Auta, J. M. Davis et al., “Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study,” Archives of General Psychiatry, vol. 57, no. 11, pp. 1061–1069, 2000.
- S. H. Fatemi, J. A. Earle, and T. McMenomy, “Reduction in Reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression,” Molecular Psychiatry, vol. 5, no. 6, pp. 654–663, 2000.
- S. H. Fatemi, J. M. Stary, and E. A. Egan, “Reduced blood levels of reelin as a vulnerability factor in pathophysiology of autistic disorder,” Cellular and Molecular Neurobiology, vol. 22, no. 2, pp. 139–152, 2002.
- S. L. Eastwood and P. J. Harrison, “Interstitial white matter neurons express less reelin and are abnormally distributed in schizophrenia: towards an integration of molecular and morphologic aspects of the neurodevelopmental hypothesis,” Molecular Psychiatry, vol. 8, no. 9, pp. 821–831, 2003.
- N. R. Smalheiser, E. Costa, A. Guidotti et al., “Expression of reelin in adult mammalian blood, liver, pituitary pars intermedia, and adrenal chromaffin cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 3, pp. 1281–1286, 2000.
- S. H. Fatemi, J. L. Kroll, and J. M. Stary, “Altered levels of Reelin and its isoforms in schizophrenia and mood disorders,” NeuroReport, vol. 12, no. 15, pp. 3209–3215, 2001.
- G. Lugli, J. M. Krueger, J. M. Davis, A. M. Persico, F. Keller, and N. R. Smalheiser, “Methodological factors influencing measurement and processing of plasma reelin in humans,” BMC Biochemistry, vol. 4, article 9, 2003.
- F. Tissir and A. M. Goffinet, “Reelin and brain development,” Nature Reviews Neuroscience, vol. 4, no. 6, pp. 496–505, 2003.
- J. Herz and Y. Chen, “Reelin, lipoprotein receptors and synaptic plasticity,” Nature Reviews Neuroscience, vol. 7, no. 11, pp. 850–859, 2006.
- J. T. Rogers and E. J. Weeber, “Reelin and apoE actions on signal transduction, synpatic function and memory formation,” Neuron Glia Biology, vol. 4, pp. 259–270, 2008.
- E. Dong, H. Caruncho, W. S. Liu et al., “A reelin-integrin receptor interaction regulates Arc mRNA translation in synaptoneurosomes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 9, pp. 5479–5484, 2003.
- H. J. Caruncho, I. G. Dopeso-Reyes, M. I. Loza, and M. A. Rodriguez, “GABA, reelin, and the neurodevelopmental hypothesis of schizophrenia,” Critical Reviews in Neurobiology, vol. 16, no. 1-2, pp. 25–32, 2004.
- Y. Chen, J. Qin, J. Cai, and Z. W. Chen, “Cold induces micro- and nano-scale reorganization of lipid raft markers at mounds of T-cell membrane fluctuations,” PLoS One, vol. 4, no. 4, article e5386, 2009.
- P. Tueting, E. Costa, Y. Dwivedi et al., “The phenotypic characteristics of heterozygous reeler mouse,” Neuroreport, vol. 10, no. 6, pp. 1329–1334, 1999.
- J. Podhorna and M. Didriksen, “The heterozygous reeler mouse: behavioural phenotype,” Behavioural Brain Research, vol. 153, no. 1, pp. 43–54, 2004.
- P. Tueting, M.-S. Doueiri, A. Guidotti, J. M. Davis, and E. Costa, “Reelin down-regulation in mice and psychosis endophenotypes,” Neuroscience and Biobehavioral Reviews, vol. 30, no. 8, pp. 1065–1077, 2006.
- G. Laviola, E. Ognibene, E. Romano, W. Adriani, and F. Keller, “Gene-environment interaction during early development in the heterozygous reeler mouse: clues for modelling of major neurobehavioral syndromes,” Neuroscience and Biobehavioral Reviews, vol. 33, no. 4, pp. 560–572, 2009.
- J. M. Green-Johnson, S. Zalcman, C. Y. Vriend, D. M. Nance, and H. Greenberg, “Suppressed T cell and macrophage function in the ‘reeler’ (rl/rl) mutant, a murine strain with elevated cerebellar norepinephrine concentration,” Brain, Behavior, and Immunity, vol. 9, no. 1, pp. 47–60, 1995.
- V. Strasser, D. Fasching, C. Hauser et al., “Receptor clustering is involved in reelin signaling,” Molecular and Cellular Biology, vol. 24, pp. 1378–1386, 2004.
- L. Groc, D. Choquet, F. A. Stephenson, D. Verrier, O. J. Manzoni, and P. Chavis, “NMDA receptor surface trafficking and synaptic subunit composition are developmentally regulated by the extracellular matrix protein reelin,” Journal of Neuroscience, vol. 27, no. 38, pp. 10165–10175, 2007.
- E. Ognibene, W. Adriani, A. Caprioli et al., “The effect of early maternal separation on brain derived neurotrophic factor and monoamine levels in adult heterozygous reeler mice,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 32, no. 5, pp. 1269–1276, 2008.
- E. G. Gilerovich and I. P. Grigor'ev, “Gaba- and serotonin-immunoreactive structures and -binding protein in the neocortex of the reeler mouse mutant,” Neuroscience and Behavioral Physiology, vol. 35, no. 9, pp. 887–890, 2005.
- S. H. Fatemi, “Reelin mutations in mouse and man: from reeler mouse to schizophrenia, mood disorders, autism and lissencephaly,” Molecular Psychiatry, vol. 6, no. 2, pp. 129–133, 2001.
- A. M. Persico, L. D'agruma, N. Maiorano et al., “Reelin gene alleles and haplotypes as a factor predisposing to autistic disorder,” Molecular Psychiatry, vol. 6, no. 2, pp. 150–159, 2001.
- S. H. Fatemi, J. M. Stary, A. R. Halt, and G. R. Realmuto, “Dysregulation of reelin and Bcl-2 proteins in autistic cerebellum,” Journal of Autism and Developmental Disorders, vol. 31, no. 6, pp. 529–535, 2001.
- S. H. Fatemi, “The role of Reelin in pathology of autism,” Molecular Psychiatry, vol. 7, no. 9, pp. 919–920, 2002.
- S. H. Fatemi, A. V. Snow, J. M. Stary et al., “Reelin signaling is impaired in autism,” Biological Psychiatry, vol. 57, no. 7, pp. 777–787, 2005.
- P. M. Whitaker-Azmitia, “Behavioral and cellular consequences of increasing serotonergic activity during brain development: a role in autism?” International Journal of Developmental Neuroscience, vol. 23, no. 1, pp. 75–83, 2005.
- I. M. McNamara, A. W. Borella, L. A. Bialowas, and P. M. Whitaker-Azmitia, “Further studies in the developmental hyperserotonemia model (DHS) of autism: social, behavioral and peptide changes,” Brain Research, vol. 1189, no. 1, pp. 203–214, 2008.
Copyright © 2010 Tania Rivera-Baltanas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.